Panel Discussion: Didactic Session 1: Prostate Biopsy

James A. Eastham, MD, FACS, is the Peter T. Scardino Chair in Oncology and Chief of the Urology Service in the Department of Surgery at Memorial Sloan-Kettering Cancer Center in New York. Dr. Eastham received his medical degree from the University of Southern California, Los Angeles. He completed an Internship in General Surgery and a Residency in Urology at Los Angeles County+USC Medical Center. He went on to complete a Fellowship in Urologic Oncology at Baylor College of Medicine in Houston, Texas. Prior to his appointment at Memorial Sloan-Kettering Cancer Center, Dr. Eastham was an Assistant and Associate Professor in the Department of Urology at Louisiana State University in Shreveport and Chief of Urology at Overton-Brooks Veterans Administration Medical Center in Louisiana.

Dr. Eastham’s research has focused on the prevention and treatment of prostate cancer, and he has a particular interest in improving oncologic and quality-of-life outcomes after radical prostatectomy. He has authored or co-authored over 300 articles which have appeared in peer-reviewed journals such as the Journal of the American Medical Association, the Journal of Urology, the Journal of Clinical Oncology, Urology, and Transplantation. In addition, he has authored numerous book chapters, reviews, monographs, and abstracts. He is a Fellow of the American College of Surgeons and a member of several professional societies, including the American Urologic Association, the Society of Urologic Oncology, and the Societé Internationale D’Urologie.

Leonard S. Marks, MD, is Professor and inaugural holder of the deKernion Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles. He graduated from the University of Texas Medical Branch, where he received his MD with AOA honors and his MA in Physiology in 1969. He served an internship and surgical residency at UCLA/Harbor General Hospital. For the following two years, he served on active duty as Lieutenant Commander in the US Public Health Service. He was named a Post-Doctoral Research Scholar at UCLA School of Medicine in 1973-4. He completed his Urology Residency at UCLA and was a Lecturer in Urology there in 1978, following which he entered private practice in Los Angeles. He re-joined the UCLA faculty full-time in 2009.

While in practice, Dr. Marks founded a non-profit research organization, the Urological Sciences Research Foundation, a 501c3 corporation, to further his academic interests. He became an original AFUD scholar in 1992 for work relating serum PSA levels to prostate histology. He received a Prostate Cancer Foundation (PCF) research award in 2000 for cross-cultural studies of prostate cancer. As an early advocate of multimedia in medical education, he served as Website Editor of Urology for The Gold Journal from 1998-2010. For his work in the scientific evaluation of alternative medicines, he was appointed to committees of the American Urological Association, the National Institutes of Health, and the National Academy of Sciences.

Over the past decade, he has been Principle Investigator of three separate R01 Awards from the National Cancer Institute devoted to targeted prostate biopsy and focal therapy of prostate cancer. He has authored more than 150 scientific publications.

Dr. Gorin is an Associate Professor of Urology in the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai. Dr. Gorin attended college at the University of Michigan, earning a Bachelor of Science in Cellular and Molecular Biology. He then attended medical school at the University of Miami Leonard M. Miller School of Medicine, where he graduated as an inductee to the Alpha Omega Alpha Honor Medical Society. Following medical school, Dr. Gorin completed a general surgery internship, urology residency, and fellowship in endoscopic and minimally invasive urology at the James Buchanan Brady Urological Institute at Johns Hopkins University School of Medicine.
Dr. Gorin is an internationally recognized expert on the use of molecular imaging techniques in the diagnosis and management of urologic malignancies. He is also widely recognized for his work developing novel methods for performing MRI-guided transperineal prostate biopsy and focal ablative treatments for prostate cancer. As a fellowship-trained endourologist, Dr. Gorin’s clinical practice primarily focuses on caring for patients with kidney stones, lower urinary tract symptoms, and prostate cancer.
Dr. Gorin has published over 300 articles in peer-reviewed journals with collaborators from around the world. Additionally, he has contributed to multiple medical textbooks, including chapters in Campbell-Walsh-Wein Urology, The 5-Minute Urology Consult, and Gray’s Anatomy. In July 2022, Dr. Gorin was selected to serve as Editor-in-Chief of BJUI Compass, the open-access companion journal to the BJU International. Dr. Gorin also serves on the editorial boards of several other journals, including UROLOGY (the Gold Journal), Urologic Oncology: Seminars and Original Investigations, and the World Journal of Urology. Dr. Gorin has received numerous honors and awards for his scholarly work, including the Drs. Carl and Barbara Alving Endowed Award for Outstanding Biomedical Research from the University of Miami Miller School of Medicine and the William F. Rienhoff, Jr., M.D. Scholar Award from Johns Hopkins University School of Medicine.

Nelson N. Stone, MD, is Professor of Urology, Radiation Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and chief medical officer at Viomerse, Inc.

Dr. Stone earned his medical degree from the University of Maryland in 1979. He completed a Residency in General Surgery in 1981 at the University of Maryland, followed by a Residency in Urology at the University of Maryland. He then completed a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center and a Research Fellowship in Biochemical Endocrinology at Rockefeller University in 1986. He was Chief of Urology at Elmhurst Hospital Queens from 1986-1996.

Dr. Stone has founded several medical companies and serves on the editorial board of many scientific journals. He is a member of many professional societies, including the Prostate Conditions Education Council, the Society for Minimally Invasive Therapy, the New York State Urological Society, the American Association of Clinical Urologists, and the American Urologic Association. Dr. Stone has participated in approximately 25 research studies on prostate cancer and has authored more than 500 articles, abstracts, and book chapters, primarily on prostate cancer. He invented the real-time technique for prostate brachytherapy in 1990 and has trained more than 5,000 physicians worldwide through his company ProSeed. His most recent company, Viomerse, creates synthetic body parts (phantoms) for surgical training and has recently released an extended reality remote training platform.

Arvin George, MD, serves as Director of Prostate Cancer Programs and Associate Professor (PAR) of Urology at Johns Hopkins School of Medicine in Baltimore, Maryland. He is a urologic surgeon who specializes in the diagnosis and management of genitourinary cancers. After obtaining his medical degree from the Royal College of Surgeons in Ireland, he completed his urology residency at the Smith Institute for Urology at the Hofstra North Shore-LIJ School of Medicine. He remained there to complete his endourology fellowship in New York, gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. George’s research interests include minimally-invasive and image-guided treatments, functional prostate imaging, and focal therapy for prostate cancer. His research aims to identify appropriate use for imaging in diagnosis, risk stratification, and management of prostate cancer, including active surveillance and selection/treatment of patients with novel focal therapy modalities.